BioMarin Pharmaceutical Inc (NASDAQ:BMRN) reached an intraday high of $70.17 on Friday


Dallas, Texas 11/18/2013 (Financialstrend) – In Friday’s trading session, BioMarin Pharmaceutical Inc (NASDAQ:BMRN) rose by 7.71%. The shares opened at a price of $63.99, which touched the intraday high of $70.17 and headed to a close of $69.29. Around 4.86 million exchanged hands over the trading day and an average volume of 2.14 million shares were traded over a 30 day period. The 52-week low of BioMarin Pharmaceutical Inc (NASDAQ:BMRN) shares is $46.53 and its 52-week high is $80.67. The company has a market capitalization of $9.85 billion.                                        

About the company

BioMarin Pharmaceutical Inc (NASDAQ:BMRN) was incorporated on 25 October, 1996. The company develops & commercializes pharmaceuticals that are used for the treatment of  serious diseases & medical conditions. Its product portfolio is made up  of 4 approved products & multiple investigational-product candidates. The Approved-products include Naglazyme, Kuvan, Aldurazyme & Firdapse (amifampridine phosphate). BioMarin Pharmaceutical Inc (NASDAQ:BMRN) is conducting different clinical trials on various product candidates for  treating various diseases. This includes Vimizim which was previously  referred to as GALNS. This is  an enzyme-replacement therapy that is used to treat Mucopolysaccharidosis Type IV / Morquio Syndrome Type A , PEG-PAL, the enzyme-substitution therapy for  treating phenylketonuria (PKU), BMN-701, the  enzyme-replacement therapy for the Pompe disease, a glycogen-storage disorder.

The company  also has under trial another drug candidate, BMN-673. This is an orally available poly-polymerase, or PARP-inhibitor that is used to treat  certain cancers& BMN-111, which is a peptide-therapeutic for treating achondroplasia. On 7 January, 2013, BioMarin Pharmaceutical Inc (NASDAQ:BMRN) acquired Zacharon Pharmaceuticals.

BioMarin Pharmaceutical Inc (NASDAQ:BMRN is conducting / planning on conducting preclinical-development of various other enzyme-product candidates for genetic & other metabolic-diseases, such as BMN-190 for treating late infantile-neuronal ceroid lipofuscinosis. This is  a kind of Batten disease. BioMarin Pharmaceutical Inc (NASDAQ:BMRN) is developing Vimizim- this is an enzyme replacement therapy for treating  MPS IV A, which is a lysosomal-storage disorder.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.